EBA-175 RII-NG Malaria Vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Plasmodium Falciparum Malaria

Phase 1

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

CompletedNCT00347555

National Institute of Allergy and Infectious Diseases (NIAID)Plasmodium Falciparum Malaria

Start: 2006-05-31End: 2008-04-30Updated: 2013-04-12

EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults

CompletedNCT01026246

National Institute of Allergy and Infectious Diseases (NIAID)Plasmodium Falciparum Malaria

Start: 2010-06-30End: 2012-03-31Updated: 2013-03-29

Related Papers

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study

PLoS ONE2016-09-1926 citations